News
Mycovia Pharmaceuticals Announces Presentation of Oteseconazole (VT-1161) Phase 3 Data Demonstrating Safety and Efficacy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) at the 2021 IDSOG Annual Meeting
Durham, N.C. – July 29, 2021 – Mycovia Pharmaceuticals, Inc. (Mycovia), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today announced that data from its Phase 3, randomized, double-blind, placebo-controlled VIOLET studies to measure the efficacy and safety of oteseconazole (VT-1161) for the treatment of recurrent vulvovaginal candidiasis (RVVC) will be presented at the 2021 Virtual Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG). Dr. Jack Sobel, Distinguished Professor of Internal Medicine, Division of Infectious Diseases, and Dean Emeritus at Wayne State University, will lead the oral presentation of the VIOLET data during IDSOG’s Scientific Session 1 on Thursday, July 29 at 10:45 a.m. EST.